Neurocrine Biosciences Stock News

Voyager Therapeutics Inc (NASDAQ:VYGR) shares have jumped on the news that the biotechnology company has entered into a strategic collaboration with Neurocrine Biosciences (NASDAQ:NBIX) Inc to advance

Biotechnology has often been among the most popular sectors in the MoneyShow Top Picks report, our annual survey of the nation's leading newsletter advisors. This year's report is no exception; here's

Shares of Voyager Therapeutics Inc. VYGR, +10.65% rallied 35% in premarket trading on Monday after the company announced a deal with Neurocrine Biosciences Inc. NBIX, +0.06% to develop and commerciali

William Blair & Company's report outlined some key themes and significant trends to monitor while entering 2023, providing its top stock ideas for the upcoming 12-month period. Seagen Inc.'s (NASD

Neurocrine Biosciences Inc's (NASDAQ: NBIX) NBI-827104 did not meet its primary endpoint in the Phase 2 STEAMBOAT study compared to placebo in pediatric patients with epileptic encephalopathy with

With analysts expecting a whopping 3,755% Q4 growth, H.F. Sinclair leads this list of 24 of today's fastest-growing stocks.

Top biotech stocks surge within the IBD 50. Some pass buy points while others build bases.

BTIG cut the price target on Gain Therapeutics, Inc. (NASDAQ: GANX) from $30 to $10. BTIG analyst Thomas Shrader maintained a Buy rating on the stock. Gain Therapeutics shares rose 1.3% to close at $

Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday's high of $125.99. It is forming a bullish channel.

As Leaderboard stocks Enphase Energy, Wingstop and Cheniere Energy navigate Fed rate hikes, all eyes now turn to the midterm elections. The post Three Stocks Rise, Watchlist Grows With Midterm Electio

Neurocrine (NBIX) could produce exceptional returns because of its solid growth attributes.

Zoetis' (ZTS) earnings miss estimates in third-quarter 2022. Revenues, though up, also miss estimates due to the supply constraints in the international market. Zoetis lowers its financial guidance.

Neurocrine (NBIX) delivered earnings and revenue surprises of -17.86% and 2.61%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Q3 2022 Earnings Conference Call November 1, 2022 8:00 AM ET Company Participants Todd Tushla - VP of IR Kevin Gorman - CEO Matt Abernethy - CFO Eric Benevi

Neurocrine (NBIX) delivered earnings and revenue surprises of -17.86% and 2.61%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?